Oxford BioMedica Announces FDA Approval for TroVax Phase II Study in Prostate Cancer

Oxford BioMedica has received approval from the US Food and Drug Administration (FDA) and Recombinant DNA Advisory Committee (RAC) to initiate a clinical Phase II study in the United States to assess the activity of TroVax® (MVA-5T4) in patients with progressive hormone refractory prostate cancer (HRPC)

Oxford, UK | July 26, 2010 | Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, announces that it has received approval from the US Food and Drug Administration (FDA) and Recombinant DNA Advisory Committee (RAC) to initiate a clinical Phase II study in the United States to assess the activity of TroVax® (MVA-5T4) in patients with progressive hormone refractory prostate cancer (HRPC).

The randomised, open-label Phase II study will enroll 80 patients with metastatic HRPC in five centres across the US and will assess the activity of TroVax® plus chemotherapy drug Docetaxel (Taxotere®), versus Docetaxel alone. The study will be led by Professor Anna Ferrari, NYU Clinical Cancer Center, and is anticipated to be initiated by the end of Q3 2010.

Prostate cancer is the second most common cancer in men worldwide. Prostate cancer hormone therapy involves the removal of the body’s testosterone supply which, for a period of time, will slow or stop the growth and spread of prostate cancer. Hormone refractory prostate cancer occurs when hormone therapy fails to stop the growth of prostate cancer.

John Dawson, Chief Executive Officer at Oxford BioMedica, said: "Receiving FDA and RAC approval is a significant final step in the planning of this study of TroVax® in patients with HRPC and follows positive analysis of the TRIST clinical study. We intend this study to be followed by a series of investigator-led clinical studies and we are pleased to continue the clinical development of TroVax®. With the study design now in place, we look forward to recruiting our first patient and advancing the development of TroVax® in an important disease area."

Oxford BioMedica plc

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company’s technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen-Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

TroVax®

TroVax® is Oxford BioMedica’s therapeutic cancer vaccine, which is designed to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax® targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a Modified Vaccinia Ankara vector, which delivers the gene for 5T4 and stimulates a patient’s body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4 antigen.

SOURCE: Oxford BioMedica

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top